Patients who undergo narrowband UV-B phototherapy for vitiligo have no increased risk of developing skin cancer, but long-term therapy is associated with higher odds of actinic keratosis, researchers say.

In the Korean study of more than 60,000 patients with vitiligo in a national health insurance database — two-thirds of whom had the phototherapy — no link was found with melanoma or non-melanoma skin cancer over 10 years of follow-up.